PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Ovintiv Inc. (OVV)
40.910.33 (-0.80%)
40.40 - 41.05
29.80 - 47.18
2.12M / 3.66M (Avg.)
18.02 | 2.27
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
64.66%
Net income growth above 1.5x VET's 31.72%. David Dodd would see a clear bottom-line advantage if it is backed by stable operations.
-16.67%
Negative yoy D&A while VET is 7.09%. Joel Greenblatt would note a short-term EPS advantage unless competitor invests for future advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-156.97%
Both reduce yoy usage, with VET at -139.45%. Martin Whitman would find an industry or cyclical factor prompting leaner operational approaches.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-156.97%
Both reduce yoy usage, with VET at -139.45%. Martin Whitman would suspect an industry or cyclical factor pulling back on these items.
115.40%
Some yoy increase while VET is negative at -97.37%. John Neff would see competitor possibly reining in intangible charges or revaluations more effectively than we do.
-57.57%
Both yoy CFO lines are negative, with VET at -45.90%. Martin Whitman would suspect cyclical or cost factors harming the entire niche’s cash generation.
24.93%
Lower CapEx growth vs. VET's 98.32%, potentially boosting near-term free cash. David Dodd would confirm no missed expansions that competitor might exploit.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-133.05%
Both yoy lines negative, with VET at -129.87%. Martin Whitman suspects a cyclical or strategic rationale for cutting extra invests in the niche.
-5.79%
Both yoy lines negative, with VET at -63.50%. Martin Whitman suspects a broader cyclical shift away from heavy investing across the niche.
No Data
No Data available this quarter, please select a different quarter.
174.82%
Issuance growth of 174.82% while VET is zero at 0.00%. Bruce Berkowitz sees a mild dilution that must be justified by expansions or acquisitions vs. competitor’s stable share base.
No Data
No Data available this quarter, please select a different quarter.